124 related articles for article (PubMed ID: 32213303)
1. Soluble urokinase receptor as a predictor of non-cardiac mortality in patients with percutaneous coronary intervention treated ST-segment elevation myocardial infarction.
Sandø A; Schultz M; Eugen-Olsen J; Køber L; Engstrøm T; Kelbæk H; Jørgensen E; Saunamäki K; Holmvang L; Pedersen F; Tilsted HH; Høfsten D; Helqvist S; Clemmensen P; Iversen K
Clin Biochem; 2020 Jun; 80():8-13. PubMed ID: 32213303
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
Lyngbæk S; Marott JL; Møller DV; Christiansen M; Iversen KK; Clemmensen PM; Eugen-Olsen J; Jeppesen JL; Hansen PR
Am J Cardiol; 2012 Dec; 110(12):1756-63. PubMed ID: 22981263
[TBL] [Abstract][Full Text] [Related]
3. Left atrial volume index: Can it provide additional prognostic information in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention?
Cordeiro F; Silva Mateus P; Leão S; Moz M; Trigo J; Ferreira C; Carvalho SS; Ferreira A; Moreira JI
Rev Port Cardiol (Engl Ed); 2018 Oct; 37(10):799-807. PubMed ID: 30318188
[TBL] [Abstract][Full Text] [Related]
4. The relationship between post-procedural platelet count and left ventricular aneurysm in patients with acute anterior ST-segment elevation myocardial infarction following primary percutaneous coronary intervention.
Wang Z; Ren L; Liu N; Peng J
Kardiol Pol; 2018; 76(5):899-907. PubMed ID: 29313561
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction).
Pu J; Ding S; Ge H; Han Y; Guo J; Lin R; Su X; Zhang H; Chen L; He B;
Circulation; 2017 Oct; 136(16):1462-1473. PubMed ID: 28844990
[TBL] [Abstract][Full Text] [Related]
6. Cardio-Renal Biomarker Soluble Urokinase-Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Patients With Coronary Artery Disease Independent of Troponin, C-Reactive Protein, and Renal Function.
Nikorowitsch J; Borchardt T; Appelbaum S; Ojeda F; Lackner KJ; Schnabel RB; Blankenberg S; Zeller T; Karakas M
J Am Heart Assoc; 2020 Apr; 9(8):e015452. PubMed ID: 32299288
[TBL] [Abstract][Full Text] [Related]
7. Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes.
Peiró ÓM; Cediel G; Bonet G; Rojas S; Quintern V; Carrasquer A; González-Del-Hoyo M; Sanz E; Bardají A
Biomarkers; 2020 Jul; 25(5):402-409. PubMed ID: 32551985
[No Abstract] [Full Text] [Related]
8. High Serum Secreted Frizzled-Related Protein 5 Levels Associates with Early Improvement of Cardiac Function Following ST-Segment Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention.
Du Y; Zhao Y; Zhu Y; Hu C; Zhang J; Ji Q; Liu W; Han H; Yang L; Zhang D; Tong S; Wang Z; Guo Y; Liu X; Zhou Y
J Atheroscler Thromb; 2019 Oct; 26(10):868-878. PubMed ID: 30773518
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of fibrinogen-to-albumin ratio to predict no-reflow and short-term prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Zhao Y; Yang J; Ji Y; Wang S; Wang T; Wang F; Tang J
Heart Vessels; 2019 Oct; 34(10):1600-1607. PubMed ID: 30993442
[TBL] [Abstract][Full Text] [Related]
10. Impact of chronic obstructive pulmonary disease on in-hospital morbidity and mortality in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention.
Șerban RC; Hadadi L; Șuș I; Lakatos EK; Demjen Z; Scridon A
Int J Cardiol; 2017 Sep; 243():437-442. PubMed ID: 28506549
[TBL] [Abstract][Full Text] [Related]
11. Contrast-induced acute kidney injury and mortality in ST elevation myocardial infarction treated with primary percutaneous coronary intervention.
Silvain J; Nguyen LS; Spagnoli V; Kerneis M; Guedeney P; Vignolles N; Cosker K; Barthelemy O; Le Feuvre C; Helft G; Collet JP; Montalescot G
Heart; 2018 May; 104(9):767-772. PubMed ID: 29092921
[TBL] [Abstract][Full Text] [Related]
12. Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial).
Spitaleri G; Brugaletta S; Scalone G; Moscarella E; Ortega-Paz L; Pernigotti A; Gomez-Lara J; Cequier A; Iñiguez A; Serra A; Jiménez-Quevedo P; Mainar V; Campo G; Tespili M; den Heijer P; Bethencourt A; Vazquez N; Valgimigli M; Serruys PW; Sabaté M
Am J Cardiol; 2018 May; 121(9):1039-1045. PubMed ID: 29544865
[TBL] [Abstract][Full Text] [Related]
13. Serial measurements of neutrophil gelatinase-associated lipocalin: prognostic value in patients with ST-segment elevation myocardial infarction treated with a primary percutaneous coronary intervention.
Lim YM; Moon JY; Min D; Kim SH; Yang WI; Kim WJ; Sung JH; Kim IJ; Lim SW; Cha DH
Coron Artery Dis; 2017 Dec; 28(8):690-696. PubMed ID: 28737526
[TBL] [Abstract][Full Text] [Related]
14. Cardiac and Noncardiac Causes of Long-Term Mortality in ST-Segment-Elevation Acute Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention.
Yamashita Y; Shiomi H; Morimoto T; Yaku H; Furukawa Y; Nakagawa Y; Ando K; Kadota K; Abe M; Nagao K; Shizuta S; Ono K; Kimura T;
Circ Cardiovasc Qual Outcomes; 2017 Jan; 10(1):. PubMed ID: 28073848
[TBL] [Abstract][Full Text] [Related]
15. Acute Myocardial Infarction: Changes in Patient Characteristics, Management, and 6-Month Outcomes Over a Period of 20 Years in the FAST-MI Program (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) 1995 to 2015.
Puymirat E; Simon T; Cayla G; Cottin Y; Elbaz M; Coste P; Lemesle G; Motreff P; Popovic B; Khalife K; Labèque JN; Perret T; Le Ray C; Orion L; Jouve B; Blanchard D; Peycher P; Silvain J; Steg PG; Goldstein P; Guéret P; Belle L; Aissaoui N; Ferrières J; Schiele F; Danchin N;
Circulation; 2017 Nov; 136(20):1908-1919. PubMed ID: 28844989
[TBL] [Abstract][Full Text] [Related]
16. Immediate complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease treated by primary percutaneous coronary intervention: Insights from the ORBI registry.
Pimor A; Auffret V; Didier R; Delaunay R; Filippi E; Hacot JP; Saouli D; Rouault G; Druelles P; Bot E; Coudert I; Boulanger B; Le Guellec M; Boulmier D; Leurent G; Bedossa M; Gilard M; Le Breton H
Arch Cardiovasc Dis; 2018 Nov; 111(11):656-665. PubMed ID: 29229216
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of myeloperoxidase concentration in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.
Kacprzak M; Zielinska M
Int J Cardiol; 2016 Nov; 223():452-457. PubMed ID: 27544604
[TBL] [Abstract][Full Text] [Related]
18. Time-of-day at symptom onset was not associated with infarct size and long-term prognosis in patients with ST-segment elevation myocardial infarction.
Sager HB; Husser O; Steffens S; Laugwitz KL; Schunkert H; Kastrati A; Ndrepepa G; Kessler T
J Transl Med; 2019 May; 17(1):180. PubMed ID: 31142323
[TBL] [Abstract][Full Text] [Related]
19. Impact of renin-angiotensin system inhibitors on long-term clinical outcomes in patients with acute myocardial infarction treated with successful percutaneous coronary intervention with drug-eluting stents: Comparison between STEMI and NSTEMI.
Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Atherosclerosis; 2019 Jan; 280():166-173. PubMed ID: 30529829
[TBL] [Abstract][Full Text] [Related]
20. Predictors of mortality in patients with non-anterior ST-segment elevation myocardial infarction: Analysis from the HORIZONS-AMI trial.
Huang X; Redfors B; Chen S; Gersh BJ; Mehran R; Zhang Y; McAndrew T; Ben-Yehuda O; Mintz GS; Stone GW
Catheter Cardiovasc Interv; 2019 Aug; 94(2):172-180. PubMed ID: 30690854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
